Insider · CIK 0001189020
Patrick Soon-Shiong
Files at PBLA (Panbela Therapeutics, Inc.), IBRX (ImmunityBio, Inc.). First filing -, latest -.
In brief
Patrick Soon-Shiong files SEC Form 4 as officer, director and 10% owner at PBLA (Panbela Therapeutics, Inc.), and also at IBRX (ImmunityBio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Patrick Soon-Shiong has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 19 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | IBRX ImmunityBio, Inc. | CConversion Common Stockindirect: See footnote | +4,606,596 | $5.43 | $25M | 251,018,873 | Apr 2, 2026 |
| Mar 31, 2026 | IBRX ImmunityBio, Inc. | CConversion Second Amended and Restated Convertible Promissory Notederivativeindirect: See footnote | - | $0.00 | - | - | Apr 2, 2026 |
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +114,329 | $0.00 | $0 | 29,816,081 | Feb 24, 2026 |
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -58,170 | $8.70 | $506k | 29,757,911 | Feb 24, 2026 |
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -114,329 | $0.00 | $0 | 114,329 | Feb 24, 2026 |
| Feb 10, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +274,122 | $0.00 | $0 | 29,820,312 | Feb 12, 2026 |
| Feb 10, 2026 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -118,560 | $6.93 | $822k | 29,701,752 | Feb 12, 2026 |
| Feb 10, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -274,122 | $0.00 | $0 | 548,246 | Feb 12, 2026 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +114,329 | $0.00 | $0 | 29,588,261 | Feb 25, 2025 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -42,071 | $3.42 | $144k | 29,546,190 | Feb 25, 2025 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -114,329 | $0.00 | $0 | 228,658 | Feb 25, 2025 |
| Feb 10, 2025 | IBRX ImmunityBio, Inc. | AGrant or award Restricted Stock Unitsderivative | +822,368 | $0.00 | $0 | 822,368 | Feb 12, 2025 |
| Feb 10, 2025 | IBRX ImmunityBio, Inc. | AGrant or award Stock Option (right to buy)derivative | +2,812,500 | $0.00 | $0 | 2,812,500 | Feb 12, 2025 |
| Dec 10, 2024 | IBRX ImmunityBio, Inc. | CConversion Common Stockindirect: See footnote | +103,710,088 | $1.94 | $201M | 232,937,105 | Dec 12, 2024 |
| Dec 10, 2024 | IBRX ImmunityBio, Inc. | CConversion Common Stockindirect: See footnote | +13,475,172 | $2.28 | $31M | 246,412,277 | Dec 12, 2024 |
| Dec 10, 2024 | IBRX ImmunityBio, Inc. | CConversion Convertible Promissory Notederivativeindirect: See footnote | - | $0.00 | - | - | Dec 12, 2024 |
| Dec 10, 2024 | IBRX ImmunityBio, Inc. | CConversion Convertible Promissory Notederivativeindirect: See footnote | - | $0.00 | - | - | Dec 12, 2024 |
| Dec 10, 2024 | IBRX ImmunityBio, Inc. | JOther Amended and Restated Promissory Notederivativeindirect: See footnote | - | $0.00 | - | - | Dec 12, 2024 |
| Dec 10, 2024 | IBRX ImmunityBio, Inc. | JOther Second Amended and Restated Convertible Promissory Notederivativeindirect: See footnote | - | $505,000,000.00 | - | - | Dec 12, 2024 |
Questions about Patrick Soon-Shiong
Answered from the filings on this page, as of the latest one.
Is Patrick Soon-Shiong buying or selling?
Patrick Soon-Shiong has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Patrick Soon-Shiong's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Patrick Soon-Shiong has 0.
Where does Patrick Soon-Shiong file Form 4?
Patrick Soon-Shiong has filed Form 4 at PBLA (Panbela Therapeutics, Inc.); IBRX (ImmunityBio, Inc.) as See remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.